Fusions of Tumor-derived Endothelial Cells with Dendritic Cells Induces Antitumor Immunity

Fusions of Tumor-derived Endothelial Cells with Dendritic Cells Induces Antitumor Immunity
复制标题

肿瘤源性内皮细胞与树突状细胞的融合诱导抗肿瘤免疫

DOI:
10.1038/srep46544
复制
发表时间:
2017-04-24
期刊:
影响因子:
4.6
通讯作者:
Zhao, Yongxiang
Zhao, Yongxiang
中科院分区:
综合性期刊3区
文献类型:
--
作者:
Huang, Yingying;Mao, Qiqi;Zhao, Yongxiang

文献摘要

被引文献

相似文献

目的探讨树突状细胞/肿瘤源性内皮细胞(DC/EC)融合细胞作为T细胞刺激因子对肿瘤进展的影响。从小鼠肝癌细胞系(H22)异种移植瘤中分离内皮细胞,从BALB/c小鼠骨髓中分离树突状细胞,体外培养内皮细胞,流式细胞仪检测内皮细胞表面CD 105的表达。采用微管形成实验和Dil-Ac-LDL摄取实验检测内皮细胞的内皮特性。以DC、EC、DC/EC融合细胞为对照组,DC/EC融合细胞为实验组,检测DC/EC融合细胞IFN-α、IFN-γ的分泌、T淋巴细胞增殖和细胞毒性T淋巴细胞(CTL)活性。体内注射经5组诱导的T淋巴细胞,检测其对肿瘤进展的影响。纯化的ECs(CD 105+)具有内皮细胞的功能,并与DCs成功融合。DC/EC融合细胞具有刺激T细胞增殖、产生IFN-α和IFN-γ的功能,在体内,DC/EC融合细胞刺激的T细胞能有效抑制肿瘤生长。融合细胞具有刺激T细胞的能力,是抗肿瘤免疫不可缺少的。
To explore dendritic cells/tumor-derived endothelial cells (DC/EC) fusion cells are potent stimulators of T cells to impact tumor progression. ECs were isolated from mice hepatoma cell line (H22) Xenograft, and dendritic cells were isolated from bone marrow of BALB/c mice, then the isolated ECs were cultured and detected the endothelial surface expression of CD105 by flow cytometry. The endothelial characteristics of ECs were detected by tube formation assay and Dil-Ac-LDL uptake assay. After the fusion with polyethylene glycol (PEG), we used DCs, ECs, DCs mixed ECs as the control groups, DC/EC fusion cells as the experimental group, Secretion of IFN-α and IFN-γ was evaluated, T lymphocyte proliferation and cytotoxic T lymphocytes (CTL) were detectedin vitro. In vivo, T lymphocyte induced by five groups was injected to detect the effect of tumor progression. Purified ECs (CD105+) took the function of endothelial cells, then successfully fused with DCs. The DC/EC fusion cells were functional in stimulating the proliferation of T cells, which produced IFN-α and IFN-γ.In vivo, T cells stimulated by DC/EC fusion cells effectively repressed tumor growth. The fusion cells, which was capable of stimulating T cells, is indispensable for antitumor immunity.